Alnylam Pharmaceuticals, Inc. (LON:0HD2)
London · Delayed Price · Currency is GBP · Price in USD 398.70
-0.79 (-0.20%)
At close: Jan 9, 2026
Alnylam Pharmaceuticals Market Cap
Alnylam Pharmaceuticals has a market cap or net worth of 39.25 billion as of January 9, 2026. Its market cap has increased by 57.21% in one year.
Market Cap
39.25B
Enterprise Value
39.29B
Revenue
2.39B
Ranking
n/a
PE Ratio
1,211.10
Stock Price
398.70
Market Cap Chart
Since May 28, 2004, Alnylam Pharmaceuticals's market cap has increased from 63.23M to 39.25B, an increase of 61,981.65%. That is a compound annual growth rate of 34.62%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 9, 2026 | 39.25B | 0.56% |
| Dec 31, 2025 | 39.03B | 61.01% |
| Dec 31, 2024 | 24.24B | 28.56% |
| Dec 29, 2023 | 18.86B | -22.29% |
| Dec 30, 2022 | 24.27B | 62.00% |
| Dec 31, 2021 | 14.98B | 35.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| AstraZeneca | 220.60B |
| GSK plc | 76.29B |
| Haleon | 33.27B |
| Smith & Nephew | 10.66B |
| Convatec Group | 4.75B |
| Hikma Pharmaceuticals | 3.47B |
| HUTCHMED (China) | 1.84B |
| Genus | 1.76B |